ArticleFrontiers in molecular biosciences2026
Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in cirrhotic patients with hepatic encephalopathy.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Hepatic encephalopathy (HE) is a severe complication of liver cirrhosis. Although traditionally considered reversible, growing evidence suggests that HE episodes may lead to persistent neuronal damage. This study aimed to evaluate the potential role of neurofilament light chain proteins (NfL) as biomarkers for detecting neuronal injury associated with HE. Method: Between 1 May 2024, and 30 April 2025, 133 patients were consecutively enrolled at the Liver Unit of the University Hospital of Messina. Exclusion criteria were neurological disorders and active alcohol use. Serum NfL concentrations were measured using SIMOA technology. The study design included two phases: 1) evaluation of NfL concentration differences across the study population, 2) analysis of correlations between NfL levels and clinical/biochemical parameters routinely used for HE diagnosis [West Haven criteria, ammonia levels, Animal Naming Test (ANT)], as well as anthropometric and nutritional indicators (BMI, handgrip strength, calf circumference). Results: The study population (56.4% males; median age 69 years) included 28 non-cirrhotic (21.1%) and 105 cirrhotic patients (78.9%), 34 of them (32.3%) with a diagnosis of HE. Statistical analysis revealed significant differences in NfL levels across the three groups (p = 0.001). ROC curve analysis demonstrated good discriminative ability of NfL for HE detection (p = 0.001, Area Under the Curve = 0.753). Significant correlations were observed between NfL levels and ANT scores (p = 0.001), West Haven grade (p = 0.05), ammonia levels (p = 0.021), low BMI (p = 0.009), reduced handgrip strength (p = 0.008) and calf circumference <31 cm (p = 0.043). Conclusion: NfL is a promising biomarker for HE. Its use in clinical practice may improve early detection and stratification of HE severity in cirrhotic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.